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Abstract
Background: Kaposi’s sarcoma (KS) is a multifocal angioproliferative tumor involving blood and lymphatic vessels,
caused by Human Herpes Virus-8 (HHV-8). KS is an important AIDS-defining tumor with high prevalence in
Sub-Saharan Africa, including Tanzania which has high HIV and HHV-8 sero-prevalence. It is critically important to monitor
the prevalence of AIDS-defining tumors, such as KS, in the age of HIV/AIDS. We studied the prevalence of KS
and associated risk factors among HIV-positive patients at Kilimanjaro Christian Medical Centre (KCMC), a referral hospital
in northern Tanzania, over the period from January 2012 to December 2015.
Methods: This was a retrospective hospital-based cross-sectional study to determine the prevalence of KS among HIV/
AIDS patients between 2012 and 2015. The study included 1100 HIV patients’ data which were collected at the Infectious
Disease Clinic (IDC) from patients’ files. Stata version 13 (StataCorp LP, Texas 77,845 USA) was used for all
statistical analyses. The prevalence of KS was calculated across levels of a number of categorical variables.
Logistic regression was performed to determine relative risk of KS for all characteristics. We included all variables with
p-values ≤10% in the multivariate analysis, including ART use, as this is considered to have an influence on KS. In the
multivariate analysis, statistical significance was established based on a two-tailed p-value ≤5%. All patients’
notes were kept confidential as per the Helsinki declaration.
Results: Our results revealed a 4.6% prevalence of KS at KCMC hospital, between January 2012 and December 2015,
51(4.6%) patients were diagnosed with KS out of 1100 HIV-positive patients. The study further revealed that KS in HIV
patients was most associated with low CD4 cell count (less than or equal to 200 cells/μl). Moreover, women were more
likely than men to diagnosed with KS, with higher odds significantly associated with KS (OR 0.42, p < 0.009). Increased
age, above 35 years, among the HIV seropositive patients was significantly associated with KS (OR 25.67, p < 0.007). HIV
patients who were none smokers were more likely to suffer from KS compared to HIV smokers (OR 0.41, p < 0.010).
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Conclusion: KS remains a common malignant vascular tumor commonly associated with HIV/AIDS in Tanzania. Our
study highlights the need for continued efforts to combat HIV, as well as associated diseases such as KS. Continued
availability of ART (Anti-Retroviral Therapy) to HIV/AIDS patients, and test reagents for CD4 cell count and viral load
determination are important measures to alleviate the suffering of these patients. Furthermore, studies to
gather more evidence on ART resistance are highly needed to guide treatment choices.
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Background
Kaposi’s sarcoma (KS) was first described in 1872 by Moritz
Kaposi, a Hungarian dermatologist, who described KS as a
rare multifocal angioproliferative tumour involving blood
and lymphatic vessels, occurring only in Eastern Europe
and the Mediterranean [1]. KS is a cancer that causes le-
sions to grow in the mucosa such as skin, mucous mem-
branes lining the mouth, nose, throat or viscerally in lymph
nodes, or other internal organs [1, 2]. KS presents as either
red, brown or purple lesions that can be typed into different
clinicopathological forms, such as patch, plaque, nodular,
lymphadenopathic or infiltrative ulcers. It can also present
as florid severe swellings in the arms, legs, face or scrotum.
The etiological agent associated with KS was discovered in
1994 and is called Human Herpes Virus 8 (HHV8), also
known as KS-associated Human Herpes Virus (KSHV) [1,
3]. There are 4 classes of KS, which include; Classic KS, En-
demic KS, Immunosuppression-associated KS and AIDS-
associated KS [4]. AIDS-associated KS is the most prevalent
form of KS, and its prevalence tremendously increased
post-HIV era but later declined due to introduction of
Anti-Retroviral Therapy (ART). However, KS still remains
one of the leading cancers in HIV-infected individuals, es-
pecially in sub-Saharan Africa, including Tanzania [5, 6].
Uldrick et al., reported post-HIV seroprevalence of KSHV
as very common in sub-Saharan Africa, with seropositivity
rates above 50%; moderately prevalent in Mediterranean
countries (20–30%), but much less common (< 10%) in
most of Europe, Asia and the US [7]. In Tanzania, the
prevalence of AIDS-related KS was reported to be 2.4% at
Bugando medical center in northwestern Tanzania from
2004 to 2014 [8], whereas Koski et al., reported prevalence
of AIDS-associated KS to have dropped from 10.1% in
2003 to 7.4% in 2011 in a study conducted at Ocean Road
Cancer Institute (ORCI), Tanzania [9]. A study conducted
from 2006 to 2007 at The Kilimanjaro Christian Medical
Centre (KCMC) Regional Dermatology Training Center
(RDTC) and Mawenzi Regional Hospital Infectious Dis-
eases Clinic in Moshi, northern Tanzania, reported a 4%
prevalence of KS [10]. These studies show that KS is still
prevalent in Tanzania. Furthermore, according to the Inter-
national Agency for Research on Cancer 2012 report, KS
accounts for approximately 12.3% of all cancer deaths in
the East African region [6].
Several risk factors have been associated with high
prevalence of KS in sub-Saharan Africa and East Africa.
The major risk factors include HIV seropositivity and
non-adherence to anti-retroviral therapy [9], as well as
low CD4 cell levels [3, 11, 12]. In contrast, injecting drug
users and homosexuals are the highest risk groups for KS
in developed countries, such as the United States of
America [11], where it is estimated that 30–40% of homo-
sexual men infected with HIV are seropositive for HHV-8
[11]. Similar observations were made in India, where
Munawwar et al., reported the major risk factor for KS
among HIV patients to be seropositivity to HHV-8, which
accounted for 26.0% in heterosexual men and 25% in men
who had sex with other men (MSM) developed KS [13].
Treatment options for KS include surgical excision, radi-
ation therapy and intralesional chemotherapy. These treat-
ment options are used based on disease severity and
available local treatment options. Highly Active Anti-Retro-
viral Therapy (HAART) is recommended to reduce the ex-
tent and size of KS lesions in HIV-related KS patients.
However, recent reports have shown that ART resistance is
on the rise in southern and eastern Africa and Latin Amer-
ica and, as a result, it may soon be necessary to change the
recommended first-line antiretroviral drug regimen in
many countries to integrase inhibitor-based treatment [14].
Generally, KS continues to be one of the leading
AIDS-defining illnesses in Sub-Saharan Africa, including
Tanzania, as well as one of the most prevalent cancers
overall due to HIV and HHV-8 [13, 15]. In light of its im-
portance in the HIV era, KS is thus a critical tumor to
monitor on an annual and periodic basis, to assess the im-
pact of different preventive and management strategies in
place against the disease. The aim of this study was there-
fore to determine the prevalence of KS and associated risk
factors among HIV positive patients who attended KCMC
referral hospital in Kilimanjaro between 2012 and 2015.
Methods
Study design
This study was a hospital based retrospective cross sec-
tional study to determine prevalence of KS and associ-
ated risk factors among HIV positive patients who
attended KCMC referral hospital in northern Tanzania.
The study involved collection and analysis of secondary
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data from patients’ records from 1 January 2012 to 31
December, 2015.
Study area
This study was conducted at KCMC, a tertiary referral
hospital in Kilimanjaro region, northern Tanzania. Kili-
manjaro region has 7 districts; Moshi municipality where
the hospital is found, Moshi rural, Same, Rombo,
Mwanga, Hai and Siha. The hospital hosts the Infectious
Disease Clinic (IDC) and Regional Dermatology Training
Centre (RDTC) that are routinely attended by KS pa-
tients. The hospital serves not only the Kilimanjaro re-
gion population, but also the wider population of
northern Tanzania, estimated to be around 15 million
people. The hospital also attends patients referred from
various hospitals in Tanzania, with 500–800 outpatients
per day, and 630 official beds.
Study population
All data for HIV-positive patients who attended the IDC
at KCMC from 1 January 2012 to 31 December 2015
were included in this study. The data included patients’
HIV serostatus, CD4 cell count and ART adherence. The
data was collected at admission during the study period.
Prevalence of KS was calculated based on HIV-positive
patients diagnosed with KS in the study period. All in-
cluded patients were 18 years old and above. KS patients
were first diagnosed clinically by physical examination
by a dermatologist, followed by histological examination
of punch biopsies from suspected lesions and finally
confirmed by immunohistochemistry.
Sampling technique
Data was collected by reviewing patients’ medical re-
cords available at KCMC IDC. It included all HIV-posi-
tive patients diagnosed with KS from 1 January 2012 to
31 December 2015.
Data collection method and tools
Data collection method
Data was collected by retrospective medical records re-
view of HIV patients’ files available at the KCMC med-
ical records unit. Data on serostatus was collected first
and socio-demographic and other related data were col-
lected thereafter. Data included CD4+ cell count at ad-
mission, history of sexually transmitted diseases (STD),
history of being attended by a traditional healer, ART
use, cigarette smoking, marital status, education, resi-
dence and occupation. These data were collected from
the first visit of the patient. All included HIV patients
with KS must have been reviewed by a dermatology spe-
cialist clinically and histologically confirmed by routine
haematoxylin and eosin staining and analyzed by two
independent, trained dermatopathologists. Anti-LANA
immunohistochemistry was finally done to confirm the
histology diagnoses. The immunohistochemistry was
also used as the final confirmation where the diagnosis
was indeterminate by routine histology.
Statistical data processing and analysis
Data collection sheets were checked first for complete-
ness and accuracy. Data entry was done using MS Excel
2013; Stata v13 was used for all analyses. Categorical
variables were analyzed using Chi-square tests. T-test
was used to compare mean age of participants between
KS+ and KS-. Logistic regression analysis was used to
identify risk factors and calculate risk magnitudes by
Odds Ratio (OR). Factors included were age, gender,
marital status, occupation, smoking, visit to traditional
healer, CD4 cell counts, and STI history. Age was strati-
fied into 3 strata of 0 to 18, 19 to 35 and 35 and above
based on categories of young, young adults and older
age as per Tanzanian life expectancy. CD4 count was
stratified in stata of 0–200, 201 to 600 and 600 and
above based on the WHO categorization of 0–200 being
considered AIDS, 201 to 600 intermediate and 601 and
above is considered to be within normal range. ‘Student’
was used as the reference group for occupation so as to
be consistent with ‘age’ as students are generally ex-
pected to be in the young individuals strata. Univariate
and multivariate analyses were used to determine un-
adjusted and adjusted OR respectively. Statistical signifi-
cance was established using a two-tailed p-value ≤5% in
all analyses. We included all variables with p-values
≤10% in the multivariate analysis, including ART use, as
this is considered to have an influence on KS. The vari-
ables included in the multivariable analysis were age,
gender, marital status, occupation, smoking, traditional
healers,ART use, CD4 count and history of STIs. In the
multivariate analysis, statistical significance was estab-
lished based on a two-tailed p-value ≤5%.
Results
Socio- demographic characteristics of the study
participants
A total of 1108 HIV-positive patients’ data was retrieved
for the period from 1 January 2012 to 31 December
2015. Eight patients were excluded due to lack of vital
information on serostatus and other records. A total
number of 1100 HIV patients’ data were thus used in
this study, as summarized in Fig. 1 below. Sixty-one per-
cent of the study participants were females and 39%
were males. Approximately 61.5% had primary school
education level. About 49.6% of the study participants
were married, 56.2% resided in rural areas, and 35.7%
were peasants. The socio-demographic data is summa-
rized in Table 1 below.
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Prevalence and distribution of KS among HIV seropositive
patients by socio-demographic characteristics
Out of 1100 HIV patients, 51 (4.6%) patients were histo-
logically confirmed KS positive. KS was most prominent
in the 35+ age group. Females were significantly more
likely to present with KS (OR 0.42, p = 0.009) than
males. KS patients with CD4 cell count of less than or
equal to 200 cells/μl were more likely to have a KS diag-
nosis compared to patients with higher CD4 cell counts
of 201 and above (OR 28.46, p < 0.003). Table 2 summa-
rizes the data.
Risk factors associated with KS among HIV seropositive
patients
Our data showed that more HIV patients with CD4
count less than or equal to 200 cells/μl were more
likely to be diagnosed with KS compared to patients
with CD4 cell count above 200 cells/μl (OR 28.46, p
< 0.003). When we compared the ART users to
non-ART users by using adjusted odds ratio, the
non-ART users were not more likely to suffer from
KS compared to ART users (OR 2.07, p < 0.137).
Moreover, women were more likely than men to be
diagnosed with KS, with higher odds significantly as-
sociated with KS (OR 0.42, p < 0.009). Increased age
among the HIV seropositive patients was significantly
associated with KS (OR 25.67, p < 0.007).The age dis-
tribution in Table 2 shows patients aged over 35 years
were more likely than those below or equal to 18
years to present with KS (OR 25.67, p < 0.007). HIV
patients who were smokers were not more likely to
suffer from KS compared to HIV nonsmokers (OR
0.41, p < 0.010). Risk factors associated with KS are
summarized in Table 2 below.
Discussion
We have reported a prevalence of 4.6% KS among HIV
positive patients attending KCMC hospital in the 4-year
study period from 2012 to 2015. This prevalence is
slightly higher than that reported by Mavura et al., 2015
in the same region [10]. Furthermore, similar studies
done within the past 5 years in the same area but in dif-
ferent settings, reported lower prevalence of KS. These
studies were conducted in South Africa, northwestern
Tanzania, and northern Tanzania, and reported preva-
lences of 3.4, 2.4 and 4% respectively. Other studies con-
ducted in mediterranean countries and within the East
African region [6] reported KS prevalence of 10–20, and
12.3%, which is higher than what we have reported
herein. These differences may be due to heterogeneity in
the distribution of KS within Tanzania as well as else-
where. This may also be contributed by other factors, in-
cluding length of the study period, under/over reporting
and misdiagnosis.
Our data showed an association between CD4 cell
count and KS, where low CD4 cell count (≤200)
was associated with increased odds for KS 28.4 fold
(p = 0.003). Similar observations were made by other
studies conducted in Nigeria [16] and northwestern
Tanzania [8]. These similar findings strongly suggest
that a low CD4 cell count is associated with KS. A
possible explanation for this is that KS strongly
1108 HIV patients seen at the IDC clinic 
between 1st Jan, 2012 and 31st Dec, 2015
1100 HIV positive patients seen at 
the IDC clinic between 1st Jan, 
2012 and 31st Dec, 2015 were 
included in the study
1100 patients included and 
records analyzed
51 patients were KS 
positive by histopathology
1049 patients were KS 
negative by histopathology
8 patients were excluded due to missing 
information in their records
5 patients were missing information on 
their serostatus and 3 patients’ files could 
not be traced completely.
Fig. 1 Flow diagram showing the number of patients included and excluded in the study conducted. A flow diagram showing the number of
patients’ data included in this study. The diagram summarizes the patients found to be positive for KS among all the patients that tested positive
for HIV during the study period
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impacts on immune responses. More studies on im-
mune response mechanisms in KS will possibly help
provide explanations for observed differences in
prevalence of KS and CD4 cell count.
Furthermore, our findings pointed out that the HIV
positive non-ART users were not more associated
with KS compared to ART users. Use of ART was
not shown to have a protective effect against HIV
and thus KS as previously shown by other investiga-
tors from different geographical areas [9, 12]. Most
patients at the time of this study were eligible for
ART if they presented WHO HIV stage IV or with
CD4 cell counts < 200 cells/μl. The protective role of
ART against KS has been explored extensively by
other investigators [13, 18]. ART raises body immun-
ity in HIV infected persons, and this may indirectly
benefit KS patients, therefore the interaction between
HIV-KS and ART should be further investigated. Early
initiation of ART as per newly established WHO stan-
dards is also highly encouraged as it may as well be
protective against KS. However, there are increasing
concerns of ART resistance worldwide and more so
in East Africa [14, 17]. In addition to ART resistance,
there are policy issues that need to be addressed to
help people re-engage in care and reduce loss of pa-
tients from care, as these are important factors con-
tributing to the development of drug resistance [18].
ART drug resistance was reported to be around
14.9% in ART-naïve patients in Tanzania in 2008 and
has risen to 25.4% in 2016 [19, 20].
Our study findings showed that females were more
likely to be diagnosed with KS compared to males (p <
0.009). This observation is different from that reported
in other studies conducted in Nigeria [21] and
Dar-es-salaam [9] by Kagu et al., 2006 and Koski et al.,
2015, respectively, as well as by Ferlay et al., who re-
ported an incidence of 5.5 in males against 2.9 in fe-
males [5]. Reasons for this disparity are yet to be
elucidated. Moreover, a study done in northwestern
Tanzania reported AIDS-related KS to be more severe
and to progress faster in females. The study did not
identify reasons for the disparity, but ruled out associ-
ation with immunological responses since there was no
significant difference between CD4 cell counts in males
and females [8].
Our study observed age to be significantly associated
with KS. Patients over 35 years were 25.7 times more
likely to have KS than the age groups below (p < 0.007).
Similar findings were reported in studies conducted else-
where [10]. This may be explained by reduction of im-
munity as people get older, putting them at increased
risk for age-related chronic diseases, including cancer.
Treatment of HIV patients by traditional healers had
increased risk for suffering from KS. This may be
Table 1 Socio-demographic and prevalence of KS in different
characteristics of patients seen at IDC clinic between January
2012 and December 2015
Characteristic Kaposi sarcoma
Total (%) Negative (%) Positive (%)
Age (years)
0–18 189(17.2) 188(17.9) 1(2)
19–34 481(43.7) 463(44.1) 18(35.3)
35+ 430(39.1) 398(37.9) 32(62.7)
Gender
Male 429(39) 398(37.9) 31(60.8)
Female 671(61) 651(62.1) 20(39.2)
Marital status
Married 546(49.6) 512(48.8) 34(66.7)
Divorced(widowed 212(19.3) 206(19.6) 6(11.8)
Single 342(31.1) 331(31.6) 11(21.6)
Residence
Urban 482(43.8) 464(44.2) 18(35.3)
Rural 618(56.2) 585(55.8) 33(64.7)
Occupation
Student 275(25) 270(25.7) 5(9.8)
Employee 150(13.6) 139(13.3) 11(21.6)
Business 282(25.6) 272(25.9) 10(19.6)
Peasant 393(35.7) 368(35.1) 25(49)
Education level
No formal education 95(8.6) 87(8.3) 8(15.7)
Primary 677(61.5) 650(62) 27(52.9)
Secondary 241(21.9) 233(22.2) 8(15.7)
College 87(7.9) 79(7.5) 8(15.7)
Smoking
Smoker 241(21.9) 216(20.6) 25(49)
Non smoker 859(78.1) 833(79.4) 26(51)
Visit to traditional healers
No 913(83) 885(84.4) 28(54.9)
Yes 187(17) 164(15.6) 23(45.1)
ART use
ART user 807(73.4) 767(73.1) 40(78.4)
Non ART user 293(26.6) 282(26.9) 11(21.6)
CD4 count
0–200 405(36.8) 364(34.7) 41(80.4)
201–600 531(48.3) 522(49.8) 9(17.6)
601+ 164(14.9) 163(15.5) 1(2)
History of STIs
Have STI 208(18.9) 192(18.3) 16(31.4)
No STI 892(81.1) 857(81.7) 35(68.6)
The table summarizes the socio-demographic and prevalence characteristics of
the 1100 patients included in this study. The general characteristics of the
study population are summarized. Furthermore, we observed more KS
positivity in older patients above 35 years. More male patients were also KS
positive compared to female HIV positive patients. Other patients’
characteristics which were more common on KS patients were smoking,
attending traditional healers and low CD4+ counts
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Table 2 Risk magnitude (unadjusted OR) and Adjusted risk magnitudes (adjusted OR) association of each patient characteristic with
KS as calculated in a univariate and multivariate logistic regression analysis model
Characteristic Univariate regression Multivariate regression
ORc 95% CI Pvalue ORa 95% CI Pvalue
Age (years)
0–18 ref ref
19–34 7.31 [0.97,55.14] 0.054 10.10 [1.07,95.45] 0.044
35+ 15.12 [2.05,111.46] 0.008 25.67 [2.44,270.13] 0.007
Gender
Male ref ref
Female 0.39 [0.22,0.70] 0.002 0.42 [0.22,0.81] 0.009
Marital status
Married ref ref
Divorced(widowed 0.44 [0.18,1.06] 0.067 0.44 [0.17,1.16] 0.095
Single 0.50 [0.25,1.00] 0.051 2.34 [0.79,6.95] 0.126
Residence
Urban ref
Rural 1.45 [0.81,2.62] 0.211
Occupation
Student ref ref
Employee 4.27 [1.46,12.54] 0.008 2.10 [0.46,9.51] 0.338
Business 1.99 [0.67,5.89] 0.216 0.57 [0.12,2.65] 0.475
Peasant 3.67 [1.39,9.71] 0.009 0.99 [0.20,4.78] 0.986
Education level
No formal education ref
Primary 0.45 [0.20,1.03] 0.058
Secondary 0.37 [0.14,1.03] 0.056
College 1.10 [0.39,3.07] 0.854
Smoking
Smoker ref ref
Non smoker 0.27 [0.15,0.48] 0.000 0.41 [0.21,0.81] 0.010
Visit to Traditional healers
No ref ref
Yes 4.43 [2.49,7.89] 0.000 2.99 [1.49,6.00] 0.002
ART use
ART user ref ref
Non ART user 0.75 [0.38,1.48] 0.403 2.07 [0.79,5.40] 0.137
CD4 counts
0–200 18.36 [2.50,134.62] 0.004 28.46 [3.11,260.90] 0.003
201–600 2.81 [0.35,22.35] 0.329 3.88 [0.43,35.50] 0.229
600+ ref ref
History of STIs
Have STI ref ref
No STI 0.49 [0.27,0.90] 0.022 0.53 [0.26,1.09] 0.083
This table summarizes the crude and adjusted risk magnitude of KS among the patients’ different characteristics. The table gives the likelihood of acquiring KS
among the different patients’ characteristics
ORa adjusted Odds ratios
ORc crude Odds ratios
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explained by traditional healers contributing to delaying
of ART usage by HIV patients in the process of seeking
treatment from the healers, thus increasing their risk for
KS. The same finding was observed in Cameroon [22, 23].
Our results generally show that there is still need for
more well-defined approaches in curbing KS among the
HIV seroconverted patients. Moreover, the ongoing in-
terventions need to be strengthened, especially early ini-
tiation of ART regardless of CD4 cell count as
recommended by the WHO, because ART has been as-
sociated with better prognosis and prolonged life of
HIV-positive patients, including lowering of KS sero-
prevalence when proper adherence is observed. Other
interventions include increasing awareness among HIV
patients on compliance/adherence to ART; nutritional
care and support for people living with HIV/AIDS to
improve their immunity and adherence to ART; health
care education especially as patients’ age, as well as
health seeking attitude. We also propose that monitoring
of ART resistance and virological failure, as reported by
other investigators, should also be carried out in
Tanzania. Although we have not directly studied this, we
propose that there could be an association between in-
creased KS prevalence and virological failure, as reported
to be an emerging issue in HIV patient care.
Limitations
Our study had a number of limitations. Difficulty in ac-
quiring patient information from hospital files led to
limiting the number of study participants, as those pa-
tients who lacked the required information for the study
were excluded from the study. Potential confounding
factors may have been responsible for differences in the
findings. For example, genetic and hormonal differences
between males and females may have contributed to the
observed differences in the analyzed data. This also war-
rants further mechanistic studies.
Finally, our study highlights the need for continued ef-
forts in combating HIV/AIDS and its associated KS in
Tanzania. Specialized treatment for KS and other can-
cers should be advocated. This study also highlights the
need for regular evaluation of HIV/AIDS interventions
and guidelines established by the WHO against the HIV
pandemic in different zones and regions of the World,
especially in areas with the highest prevalence of HIV/
AIDS. We also propose further studies to evaluate the
level of ART resistance in the region, to elucidate its as-
sociation with prevalence of KS in HIV patients. Efforts
are undertaken in the coastal region (Dar es Salaam) and
south-central part of Tanzania, where virological failure
was recently reported to be 14.9 and 25.4% respectively.
However, we are not aware of a country-wide approach
being put in place yet.
Conclusion
KS remains a common malignant vascular tumour com-
monly associated with HIV/AIDS in Tanzania. The
prevalence of KS among HIV-positive patients at KCMC
referral hospital during 2012–2015 period has been
found to be 4.6%, and has remained around 4% in
Northern Tanzania. Our study highlights the need for
continued efforts in combating HIV, including combat-
ing its associated diseases like KS. Continued availability
of test reagents for CD4 count and viral load determin-
ation, and early initiation of ART to HIV/AIDS patients
will alleviate the suffering of these patients. Further
studies on ART resistance are highly needed to guide de-
cisions on appropriate HV/AIDS management.
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